Rossari Biotech Intrinsic Value
Rossari Biotech intrinsic value. Rossari Biotech (ROSSARI) median intrinsic value is ₹861.80 from 10 valuation models (range ₹129–₹1077), vs current price ₹430.90 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. For current market price and key ratios, visit Rossari Biotech stock price NSE.
ROSSARI Valuation Methods Summary — DCF, Graham Number & P/E
Rossari Biotech intrinsic value across 10 models vs current price ₹430.90 — upside/downside and value range per method. Compare with Rossari Biotech valuation methods to assess whether the stock is under or overvalued.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹398.40 | ₹318.72 - ₹478.08 | -7.5% | EPS: ₹33.20, Sector P/E: 12x |
| Book Value Method | asset | ₹1077.25 | ₹969.52 - ₹1184.98 | +150.0% | Book Value/Share: ₹1211.82, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹861.80 | ₹775.62 - ₹947.98 | +100.0% | Revenue/Share: ₹2560.00, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹861.80 | ₹775.62 - ₹947.98 | +100.0% | EBITDA: ₹388.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹802.65 | ₹642.12 - ₹963.18 | +86.3% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹212.48 | ₹191.23 - ₹233.73 | -50.7% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹273.57 | ₹246.21 - ₹300.93 | -36.5% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹861.80 | ₹775.62 - ₹947.98 | +100.0% | ROE: 13.8%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹951.43 | ₹856.29 - ₹1046.57 | +120.8% | EPS: ₹33.20, BVPS: ₹1211.82 |
| Dividend Yield Method | dividend | ₹129.27 | ₹116.34 - ₹142.20 | -70.0% | DPS: ₹0.50, Target Yield: 3.5% |
ROSSARI Intrinsic Value vs Market Price — All Valuation Models
Rossari Biotech fair value range ₹129–₹1077 vs current market price ₹430.90 across 10 valuation models. Read Rossari Biotech dividend policy for the complete payout history and dividend yield track record.
ROSSARI Intrinsic Value Analysis — Undervalued or Overvalued?
Rossari Biotech median intrinsic value ₹861.80, current price ₹430.90 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of ROSSARI?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Rossari Biotech (ROSSARI) is ₹861.80 (median value). With the current market price of ₹430.90, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹129.27 to ₹1077.25, indicating ₹129.27 - ₹1077.25.
Is ROSSARI undervalued or overvalued?
Based on our multi-method analysis, Rossari Biotech (ROSSARI) appears to be trading below calculated value by approximately 100.0%.
ROSSARI Financial Health — Key Ratios vs Industry Benchmarks
Rossari Biotech financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 7.45 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 13.8% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 11.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.23x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
ROSSARI Cash Flow Quality — Operating & Free Cash Flow
Rossari Biotech operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹65 Cr | ₹-45 Cr | Positive Operating Cash Flow | 6/10 |
| March 2025 | ₹137 Cr | ₹46 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹43 Cr | ₹-9 Cr | Positive Operating Cash Flow | 6/10 |
| March 2023 | ₹152 Cr | ₹62 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹29 Cr | ₹-121 Cr | Positive Operating Cash Flow | 6/10 |